Single Arm, Single Center, Open Label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA Positive Recurrent or Refractory Multiple Myeloma
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Anti BCMA CAR T cell therapy PersonGen BioTherapeutics (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors PersonGen Biotherapeutics
Most Recent Events
- 09 Dec 2020 New trial record